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 Background Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integra-
tion site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primi-
tive CML cells, but the effect of the interaction complex on the response to ABL and JAK2 inhibitors is unknown.
 Methods The AHI-1–BCR-ABL–JAK2 interaction complex was analyzed by mutational analysis and coimmunoprecipitation. 
Roles of the complex in regulation of response or resistance to ABL and JAK2 inhibitors were investigated in BCR-
ABL+ cells and primary CML stem/progenitor cells and in immunodeficient NSG mice. All statistical tests were 
two-sided.
 Results The WD40-repeat domain of AHI-1 interacts with BCR-ABL, whereas the N-terminal region interacts with JAK2; 
loss of these interactions statistically significantly increased the IM sensitivity of CML cells. Disrupting this com-
plex with a combination of IM and an orally bioavailable selective JAK2 inhibitor (TG101209 [TG]) statistically 
significantly induced death of AHI-1–overexpressing and IM-resistant cells in vitro and enhanced survival of leu-
kemic mice, compared with single agents (combination vs TG alone: 63 vs 53 days, ratio = 0.84, 95% confidence 
interval [CI] = 0.6 to 1.1, P = .004; vs IM: 57 days, ratio = 0.9, 95% CI = 0.61 to 1.2, P = .003). Combination treatment 
also statistically significantly enhanced apoptosis of CD34+ leukemic stem/progenitor cells and eliminated their 
long-term leukemia-initiating activity in NSG mice. Importantly, this approach was effective against treatment-
naive CML stem cells from patients who subsequently proved to be resistant to IM therapy.
 Conclusions Simultaneously targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may improve outcomes in 
patients destined to develop IM resistance.
  J Natl Cancer Inst;2013;105:405–423 
The defining hallmark of chronic myeloid leukemia (CML) is 
the BCR-ABL fusion gene originating in a hematopoietic stem cell 
(1–4). The BCR-ABL oncoprotein (p210BCR-ABL) encoded by this 
gene displays constitutively elevated tyrosine kinase (TK) activity 
that drives the pathogenesis of the disease by perturbing multiple 
signaling pathways, including the RAS/MAPK, PI3K/AKT, and 
Janus kinase 2 (JAK2)/ signal transducer and activator of transcrip-
tion 5 (STAT5) pathways (5,6). In particular, JAK2 physically inter-
acts with the C-terminal region of BCR-ABL and is one of the 
most prominent targets of BCR-ABL (7,8). A recent study further 
suggests that the BCR-ABL–mediated signaling pathways in CML 
cells are controlled by JAK2 through direct phosphorylation of 
tyrosine 177 of BCR-ABL oncoprotein (9).
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase 
inhibitors (TKIs), including dasatinib (DA) and nilotinib (NL), 
have been introduced into clinical practice with remarkable 
therapeutic effects on chronic-phase (CP) CML (10–13). However, 
early relapses and the emergence of IM-resistant disease at any 
time can pose major setbacks for some patients (8,14,15), usually 
due to the selection and outgrowth of preexisting subclones of cells 
with mutations in the BCR-ABL kinase domain (14,16). Clinical 
evidence indicates that single agent, molecularly targeted therapies 
do not cure most patients, as molecular remissions are rare and 
disease frequently recurs when IM is discontinued, even after 
many years of treatment (17–20). Experimental studies have also 
shown that the most primitive CML cells are largely quiescent and 
innately insensitive to TKIs (21–27). Combination therapies to 
target other proteins or pathways, in addition to BCR-ABL, appear 
to be more effective at inhibiting these cells (28–31). Recent studies 
further suggest that survival and growth of primitive CML cells 
may not even depend on BCR-ABL–TK activity (32,33). We and 
others have demonstrated that leukemic stem cells (LSCs) possess 
multiple unique features expected to promote both their innate and 
acquired resistance to TKI therapies (16,24–27,34,35). Improved 
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treatment approaches to prevent the continuous development of 
resistant subclones by targeting other key molecular elements 
active in CML LSCs are thus clearly needed.
One candidate target is Abelson helper integration site 1 (Ahi-1/ 
AHI-1), an oncogene that is upregulated in CML LSCs, together 
with BCR-ABL (34,36,37). Ahi-1/AHI-1 encodes a unique protein 
with multiple SH3 binding sites, an SH3 domain, and seven WD40 
repeats, all known mediators of protein–protein interactions (38). 
We previously demonstrated that overexpression of Ahi-1/AHI-1 
in primitive hematopoietic cells gives them a growth advantage 
in vitro and the ability to generate leukemia in vivo, synergizing 
with BCR-ABL to enhance these outcomes (39). Conversely, sta-
ble suppression of AHI-1 by small interfering RNA reduces the 
autonomous growth capability of very primitive CML cells and 
increases their response to TKIs in vitro. Importantly, AHI-1 physi-
cally interacts with BCR-ABL and JAK2 in CML cells to mediate 
these biological effects, although the nature of the direct or indirect 
interaction between AHI-1 and JAK2 still remains uncharacterized. 
We therefore hypothesized that a combination treatment strategy, 
designed to destabilize this new protein complex, might be a more 
effective approach to eliminating CML LSCs.
Materials and Methods
Retroviral and HA-Tagged Vectors and Virus Production
Ahi-1 mutant constructs, including Ahi-1SH3∆, Ahi-1SH3WD40∆, 
and Ahi-1N-ter∆, were polymerase chain reaction (PCR) amplified 
using a mouse stem cell virus (MSCV)–Ahi-1–internal ribosomal 
entry site (IRES) –yellow fluorescent protein (YFP) vector contain-
ing full-length Ahi-1 cDNA as a template (39). The constructs were 
then subcloned into the MSCV–IRES–YFP retroviral vector using 
the HapI and XhoI sites. We also cloned them into a pcDNA3–
human influenza hemagglutinin (HA) vector using its NotI and 
XbaI sites. Specific primers used are included in Supplementary 
Table 1 (available online). Constructs were verified by restriction 
enzyme digestion analysis and DNA sequencing.
Retrovirus production was performed as previously described 
(39). Briefly, retrovirus was obtained by transfecting ecotropic 
Phoenix packaging cells with each construct, and virus-containing 
supernatants were then used to transduce the murine pro-B cell 
line BaF3 and BCR-ABL–inducible BaF3 cells (40). YFP+ cells were 
then sorted by fluorescence-activated cell sorting (FACS). Several 
clonal cell lines per construct were selected. HA-tagged constructs 
were transfected into 293T cells by calcium phosphate precipita-
tion and were then lysed and the proteins extracted for immuno-
precipitation and Western blotting analyses.
Human Cells
Cells were obtained from newly diagnosed patients with CP CML 
before initiation of any TKI therapy. The clinical details of the patients 
from whom cells were obtained and their subsequent classification 
as IM responders or nonresponders, are given in Supplementary 
Table  2 (available online). Bone marrow (BM) cells were also 
obtained from healthy donors as leftover material from BM trans-
plant harvests. Informed consent was obtained, and the procedures 
used were approved by the Research Ethics Board of the University 
of British Columbia and the University of Glasgow. CD34+ cells 
(>95% pure) were isolated immunomagnetically by positive selec-
tion of cells utilizing EasySep CD34 selection kits (STEMCELL 
Technologies, Vancouver, BC, Canada) or CliniMACS (Miltenyi 
Biotec, Auburn, CA). Purity was verified by restaining the isolated 
cells with a fluorescein-isothiocyanate (FITC)–labelled antihuman 
CD34 mouse monoclonal antibody (1:100 dilution) (STEMCELL 
Technologies) or with mouse monoclonal antihuman CD34 allo-
phycocyanin (APC) (BD Biosciences, Mississauga, ON, Canada) 
(1:100 dilution) and analyzing the cells by FACS.
Reagents
TG101209 was provided by TargeGen Inc (San Diego, CA), 
reconstituted in dimethyl sulfoxide (Sigma-Aldrich, Oakville, ON, 
Canada) to 10 mM and stored at −20°C. IM and NL were obtained 
from Novartis (Basel, Switzerland) and stored at −20°C in 10 mM 
water and in dimethyl sulfoxide, respectively. DA was supplied by 
Bristol-Myers Squibb (Princeton, NJ), and a 10 mM stock solution 
of DA in dimethyl sulfoxide was stored at −20°C. An inhibitory 
concentration (IC50) value for TG was determined based on the 
half maximal (50%) inhibitory concentration of TG on K562 cells 
using the trypan blue dye exclusion method. The IC50 value was 
also determined for CD34+ CML and normal BM cells incubated 
with four growth factors (20 ng/mL interleukin 3 [IL-3], provided 
by Novartis; 20 ng/mL interleukin 6 [IL-6], provided by Cangene, 
Mississauga, ON, Canada; 100 ng/mL Flt3-ligand, provided by 
Immunex, Seattle, WA; and 20 ng/mL granulocyte colony-stimu-
lating factor [G-CSF], provided by STEMCELL Technologies).
Colony-Forming Cell and Long-Term Culture-Initiating 
Cell Assays
Colony-forming cell (CFC) assays were performed by plating 
CD34+ cells from CML patients (Supplementary Table 2, available 
online) in methylcellulose medium (supplemented with 20 ng/mL 
IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, and 20 ng/mL granulocyte 
macrophage colony-stimulating factor (GM-CSF) (STEMCELL 
Technologies) with IM (5  µM), DA (150 nM), NL (5  µM), and 
TG101209 (TG) (100 nM), alone or in combination. In some 
experiments, CD34+ CML cells were cultured with drugs for 3 or 
6 days before the remaining cells were washed and plated for CFC 
analysis.
For long-term culture-initiating cell (LTC-IC) assays, CD34+ 
CML cells were incubated with the same inhibitors in the presence 
of the four growth factors for 3  days. Untreated and inhibitor-
treated cells were then overlaid on a preestablished, irradiated 
(M2-10B4) stromal cell layer in myeloid long-term culture 
medium (STEMCELL Technologies) supplemented with 10−6 
M hydrocortisone, as previously described (41). Cultures were 
maintained for 5 weeks with weekly half-medium changes. Cells 
were then harvested and counted, and CFC assays were performed 
to obtain LTC-IC–derived CFC colonies as an indirect measure of 
the input LTC-IC number.
Cell Suspension Cultures and Viability Assays
CML cell lines (K562, K562 IMR, K562 lenti-AHI-1, K562 SH4-
bulk, and BV173) were cultured in Roswell Park Memorial Institute 
1640 media with 10% fetal bovine serum plus 100 U/mL penicillin 
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and 0.1 mg/mL streptomycin (STEMCELL Technologies). Parental 
and Ahi-1–transduced BaF3 cells were supplemented with 5 ng/mL 
murine IL-3 (STEMCELL Technologies). 293T cells and eco-
tropic packaging cells were grown in Dulbecco’s modified Eagle’s 
media with 10% fetal bovine serum, penicillin, streptomycin, and 
L-glutamine (STEMCELL Technologies). CD34+ cells were cul-
tured in Iscove’s medium with bovine serum albumin, insulin, trans-
ferrin, low density lipoproteins (BIT; STEMCELL Technologies) 
and 10−4 M 2-mercaptoethanol. Cells were cultured with or without 
TKIs or TG alone or in combination with TG in the presence of 
four growth factors. For experiments lasting 6 days, cell were washed 
and resuspended in fresh drug on day 3. Total cell counts and viabil-
ity was assessed using the trypan blue dye exclusion method.
Apoptosis Assays
Apoptosis analysis was performed using an Apoptosis Detection kit 
(BD Biosciences). Briefly, cells were stained with Annexin V phy-
coerythrin (PE) or FITC and 7-aminoactinomysin (7-AAD) (1:20 
dilution) at 24, 48, and 72 hours for each test condition and ana-
lyzed using a FACSCalibur (BD Bioscience). Total apoptotic cell 
numbers were calculated as the sum of the “early” apoptotic cells 
(Annexin V+ only) and “late” apoptotic cells (Annexin V+/7-AAD+). 
Phenotypic analysis of viable cells was performed by labeling cells 
with mouse monoclonal antihuman CD34 APC and mouse mon-
oclonal antihuman CD38 PE antibodies (BD Bioscience) (1:100 
dilution). Cells were considered positively stained if the level of 
fluorescence was above that of an isotype-matched control (BD 
Bioscience).
Quantitative Real-Time PCR Analysis
Total RNA was extracted using the Absolutely RNA Microprep 
kit (Stratagene, La Jolla, CA). Reverse transcription reactions and 
real-time PCR were performed using 25 µL of 2× SYBR Green 
PCR Master Mix (Applied Biosystems), 1 µL of 20 µM of specific 
primers, 1 to 2 µL cDNA, and water to a final volume of 50 µL. 
Specific primers to detect BCR-ABL transcripts were previously 
described (16).
Immunoprecipitation and Western Blot Analysis
Human cell lines (K562, K562 IMR, K562 lenti-AHI-1, and 
BV173) and murine cell lines (BaF3, BCR-ABL–inducible BaF3, 
and BaF3 cells overexpressing full length Ahi-1 and its mutant 
forms) were grown in complete Roswell Park Memorial Institute 
media. Cells were lysed in protein solubilization buffer, and pro-
tein concentration was determined as described previously (16). 
For immunoprecipitation, cell lysates were incubated with anti-
body at 4°C overnight (39). The immune complexes were incu-
bated with protein G or protein A bead flurry for another 2 hours 
at 4°C. The samples were then heated at 70° C for 10 minutes and 
separated on 4% to 12% NuPAGE NOvex Bis-tris gradient gels 
(Invitrogen, Burlington, ON, Canada). Gels were transferred onto 
polyvinylidene difluoride membrane of 0.2 µm pore size (Millipore, 
Billerica, MA), and membranes were incubated with specific anti-
bodies as described (16). The antibodies in this study included a 
rabbit polyclonal N-terminal AHI-1 antibody and an antimouse 
Ahi-1 mouse monoclonal antibody (1:1000 dilution) (C-mAhi-1 
M5, Applied Biological Materials Inc Vancouver, BC, Canada), 
an antimouse ABL mouse monoclonal antibody (1:1000 dilution) 
(8E9; BD Biosciences), an antimouse JAK2 rabbit monoclonal 
antibody (1:1000 dilution) (Cell signaling Technology, MA), a rab-
bit polyclonal anti-JAK2 agarose conjugated antibody (Santa Cruz 
Biotechnology), anti-phospho-JAK2 rabbit polyclonal antibodies 
(1:1000 dilution) (Cell Signaling and Epitomics Inc, Burlingame, 
CA), an antihuman STAT5 rabbit polyclonal antibody (1:1000 
dilution) (Millipore, Billeria, MA), an anti-phospho-STAT5 rabbit 
monoclonal antibody (1:1000 dilution) (Cell Signaling), an antihu-
man phospho-CRKL rabbit polyclonal antibody (1:2000 dilution) 
(Cell Signaling), an antihuman CRKL rabbit polyclonal antibody 
(1:1000 dilution) (Santa Cruz Biotechonolgy), an antiphospho-
tyrosine mouse monoclonal antibody (4G10) (1:2000 dilution) 
(Millipore, Billerica, MA), an anti-phospho-AKT rabbit polyclonal 
antibody (1:1000 dilution) (Cell Signaling), an antimouse Akt rab-
bit polyclonal antibody (1:1000 dilution) (Cell Signaling), an anti-
human phospho-ERK rabbit polyclonal antibody (1:1000 dilution), 
an antirat ERK rabbit polyclonal (1:1000 dilution), an antimouse 
GAPDH mouse monoclonal antibody (1:2000 dilution) (Sigma 
Aldrich), an antiactin mouse monoclonal antibody (1:1000 dilu-
tion) (Sigma Aldrich), and an anti-HA mouse monoclonal antibody 
(1:1000 dilution) (Applied Biological Materials Inc). The antibody 
binding membranes were incubated with horseradish peroxidase–
conjugated secondary antibody (1:5000 dilution) (Santa Cruz 
Biotechnology) for 1 hour at room temperature. The immunoreac-
tive proteins were visualized by enhanced chemiluminescence.
CRKL and STAT5 Phosphorylation Assay 
by Intracellular Staining
After 24 and 72 hours, CML cells from each condition were stained 
with a 1:10 dilution of rabbit polyclonal P-CRKL (Tyr 207) and 
rabbit polyclonal P-STAT5 (Tyr 694)  antibodies (New England 
Biolabs, Hitchin, UK) followed by incubation with a secondary 
goat antirabbit immunoglobulin G FITC–conjugated antibody 
(Sigma Chemicals) (1:50 dilution) before FACS analysis, according 
to a previously described protocol (42). The amount of P-CRKL 
and P-STAT5 in the sample were determined and expressed as a 
percentage of untreated controls.
Transplantation of Immunodeficient Mice With CML Cells
BV173 cells (2.5 × 106 input cells per treatment condition; n  =  6 
mice per group in two experiments) were cultured with or without 
1 µM IM or 0.5 µM TG or both together for 3 days. CD34+ CML 
cells (6 × 106 per treatment condition; n  =  3 mice per group for 
each condition, per patient sample) from three CML samples were 
cultured in Iscove’s minimum essential medium with 10% BIT, 
1% L-glutamine, and four growth factors plus either 1µM IM or 
100 nM TG or both or neither for 3 days. Recovered cells were then 
washed, and all cells recovered from each treatment group were 
injected intravenously into 8- to 10-week-old, sublethally irradiated 
(315 cGy) NOD/SCID–interleukin 2 receptor γ–chain-deficient 
(NSG) mice. The level of engraftment of BV173 cells in the BM 
was determined by labeling the cells with antihuman CD45 APC 
mouse monoclonal antibody (1:100 dilution), antihuman CD19 PE 
mouse monoclonal antibody (1:50 dilution), and antihuman CD20 
PE mouse monoclonal antibody (1:50 dilution) (eBioscience, 
Canada) and analyzing by FACS. Mice were monitored weekly 
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for signs of weight loss or lethargy. For in vivo oral administration 
of TKIs or TG alone and in combination, BV173 cells (2.5 × 106 
per mouse; n  =  6 mice per group) were injected intravenously 
into 8- to 10-week-old, sublethally irradiated NSG mice. Two 
weeks posttransplantation, mice were treated with vehicle (oral 
administration of water), IM (50mg/kg), TG (60mg/kg), and IM 
(50mg/kg) plus TG (60mg/kg) twice a day for 2 weeks by oral 
gavage. Mice were monitored daily for body weight changes and 
survival during and after treatments.
To monitor human cell engraftment in mice injected with pri-
mary CD34+ CML cells, BM cells were collected every 4 weeks by 
BM aspiration. Mice were then killed after 16 weeks, and BM cells 
were harvested from femurs, tibiae, and hip bones. Cells collected 
were labeled with antihuman CD45 FITC mouse monoclonal anti-
body (1:50 dilution), CD34 APC mouse monoclonal antibody (1:100 
dilution), CD19/20 PE mouse monoclonal antibody (1:50 dilution), 
CD14/15/33/66b FITC mouse monoclonal antibodies (1:50 dilu-
tion), and CD3 APC mouse monoclonal antibody (1:100 dilution, 
BD Biosciences), and the percentage of human cells was determined 
by FACS analysis. To measure the proportion of BCR-ABL+ human 
cells, BCR-ABL transcript levels in FACS-sorted human CD45+ 
cells were evaluated by quantitative reverse-transcription PCR or 
fluorescence in situ hybridization. Animal experiments were per-
formed in the Animal Resource Centre of the BC Cancer Agency 
Research Centre using procedures approved by the Animal Care 
Committee of the University of British Columbia (Vancouver).
Statistical Analysis
Results are shown as the mean value with 95% confidence 
intervals (CIs) obtained in triplicate independent experiments. 
Differences between groups were assessed using a two-sided 
Student t test for paired samples. Statistical analysis was also per-
formed in some experiments using one way analysis of variance, 
with correction for multiple group comparison using GraphPad 
Prism version 5 (http://www.graphpad.com/prism/prism.htm). 
Methods appropriate to fitting linear mixed models were used 
to analyze the endpoints of proliferation over time, CFC output, 
and changes in P-STAT5 and P-CRKL. A P value less than .05 
was considered statistically significant. For survival curve analy-
sis, median durations of survival were presented, and log-rank 
tests were used to compare median survival of mice from differ-
ent groups.
results
Interaction of Ahi-1 With Jak2 and BCR-ABL via Different 
Binding Sites
To identify and characterize the functional domains of Ahi-1 that 
are critical for its interaction with Jak2 and/or BCR-ABL, we first 
generated several Ahi-1 mutants, including an N-terminal dele-
tion mutant (Ahi-1N-ter∆, containing both SH3 and WD40-repeat 
domains), an SH3 deletion mutant (Ahi-1SH3∆), and a mutant 
in which both SH3 and the WD40 repeats were deleted (Ahi-
1SH3WD40∆) (Figure 1, A and C). We then stably transduced each 
of these mutants, or full-length Ahi-1, into BaF3 cells and BCR-
ABL–inducible BaF3 cells (Figure 1A; Supplementary Figure 1A, 
available online; Supplementary Table 1, available online) (40). It 
was noticed that relatively higher levels of full-length Ahi-1 were 
found in Ahi-1–transduced BaF3 cells than in BCR-ABL–inducible 
cells cotransduced with Ahi-1 (Figure 1A). Coimmunoprecipitation 
experiments revealed that Ahi-1 is highly expressed and stably asso-
ciated with BCR-ABL in BCR-ABL–inducible cells cotransduced 
with full-length Ahi-1 (Figure 1B, lower left panel, lane 5), consist-
ent with our previous findings in human CML cells (39). Notably, 
Ahi-1 was detected in both Ahi-1–transduced BaF3 cells (without 
BCR-ABL), as well as in BCR-ABL–inducible cells, after immuno-
precipitation with an anti-Jak2 antibody (Figure  1B, right panel, 
lanes 2 and 5). These experiments show that Ahi-1 can directly 
interact with Jak2 in a fashion that is independent of the pres-
ence of BCR-ABL. Moreover, in the same cells transduced with 
the Ahi-1N-terΔ mutant, a predicted 70-kD interaction product of 
Ahi-1 with Jak2 was not detectable (Figure 1B, right panel, lane 6), 
demonstrating a requirement for the N-terminal region of Ahi-1 
for the Ahi-1–Jak2 interaction. Nevertheless, the Ahi-1–BCR-
ABL complex could still be identified in these cells (Figure  1B, 
lower left panel, lane 6), indicating that the deleted N-terminal 
region of Ahi-1 is not required for its interaction with BCR-ABL. 
Epitope-tagged, full-length and mutant Ahi-1 constructs were 
then transiently expressed in 293T cells, with either BCR-ABL 
or Jak2, to test the reproducibility of these findings in another 
system (Supplementary Figure  1, B and C, available online). 
Analysis of the transduced 293T cells further showed that Ahi-1 
mutants with deletion of either the SH3 domain only or both the 
SH3 and WD40-repeat domains together, but not the N-terminal 
region, did not interfere with Jak2 binding (Figure 1C, left panel). 
On the other hand, Ahi-1 molecules lacking the WD40-repeat 
domain lost the ability to bind to BCR-ABL, and the presence or 
absence of the adjacent SH3 domain did not affect this interaction 
(Figure 1C, right panel, lanes 2 and 4). Thus it can be concluded 
that the WD40-repeat domain is required for interaction of Ahi-1 
with BCR-ABL, whereas the N-terminus of Ahi-1 is essential for 
its interaction with Jak2.
Effects of the Disruption of the Ahi-1–BCR-ABL–Jak2 
Complex on IM Sensitivity of BCR-ABL+ Cells
We next asked how altering the integrity of the Ahi-1–BCR-ABL–
Jak2 complex would affect the ability of IM to induce apoptosis 
and inhibit proliferation of BCR-ABL+ cells. To assess induction 
of apoptosis, BCR-ABL–inducible BaF3 cells transduced with 
full-length Ahi-1 or its mutants were incubated for 24 hours 
in the presence or absence of IM, followed by determination of 
the frequency of Annexin V+ cells. As expected, overexpression of 
full-length Ahi-1 statistically significantly reduced the frequency 
of apoptotic cells induced by IM exposure (mean percentage of 
Annexin V+ cell in BCR-ABL–inducible cells cotransduced with full-
length Ahi-1 vs BCR-ABL-inducible cells: 6.5% vs 27% in 2 µM 
IM, difference = 20.5%, 95% CI = 14.4% to 23.7%, P < .001; and 
10% vs 34% in 5µM IM, difference = 28%, 95% CI = 21% to 36%, 
P < .001) (Figure 2, A). Strikingly, cells expressing the SH3WD40∆ 
mutant displayed dramatically increased sensitivity to IM, with 
increased Annexin V+ cells compared with BCR-ABL–inducible cells 
transduced with full-length Ahi-1 (mean percentage of Annexin V+ 
cells in Ahi-1 SH3WD40Δ vs full-length Ahi-1: 64% vs 6.5% in 
2 µM IM, difference = 53%, 95% CI = 49% to 57%, P < .001; and 
JNCI | Articles 409jnci.oxfordjournals.org
69% to 10% in 5 µM IM, difference = 58%, 95% CI = 54% to 62%, 
P < .001); to a lesser extent, this was also seen in cells expressing the 
N-terΔ (17% vs 6.5% in 2 µM IM, difference = 8.9%, 95% CI = 5% 
to 13%, P < .001; 45% vs 10% in 5 µM IM, difference = 34.8%, 
95% CI = 25.6% to 44%, P < .001) and the SH3∆ mutants (34% vs 
6.5% in 2 µM IM, difference = 26.2%, 95% CI = 21.8% to 30.6%, P 
< .001; 42% vs 10% in 5 µM IM, difference = 31.6%, 95% CI = 26.8 
% to 36.3%, I < .001) (Figure 2A; data not shown for cells in the 
presence of 5 µM IM). CFC assays performed with the same cells 
showed a statistically significantly reduced ability of Ahi-1 mutants 
to form colonies in the absence of growth factors and presence of 
IM, with more statistically significant decreases in growth factor–
independent colony growth from the SH3WD40∆-transduced 
BCR-ABL–inducible cells, as compared with controls expressing 
full-length Ahi-1 (mean CFC yields of Ahi-1N-terΔ vs full-length 
Ahi-1, 62% vs 108%, difference = 46%, 95% CI = 40% to 81%, 
P < .001; Ahi-1SH3Δ, difference = 61%, 95% CI = 33% to 60%, 
P < .001; Ahi-1SH3WD40Δ, difference  =  102%, 95% CI  =  90% 
to 115%, P < .001) (Figure 2B). Together, these results indicate a 
regulatory role for the Ahi-1 complex in the response/resistance of 
BCR-ABL+ cells to IM, with the WD40-repeat and SH3 domains 
being directly involved in mediation of IM-induced apoptosis.
Figure 1. Evidence of Abelson helper integration site 1 (Ahi-1)–Janus 
kinase 2 (Jak2) and Ahi-1-BCR-ABL interactions in BCR-ABL– and Jak2-
transduced cells coexpressing Ahi-1 and its mutants. A) Schematic of 
functional domains of full-length and mutant (N-ter∆) Ahi-1. Vectors 
were transduced into BaF3 cells and BCR-ABL–inducible cells, and 
increased protein expression levels of full-length and mutant Ahi-1 
were detected by Western blotting. B) Ahi-1 (left panel) or Jak2 (right 
panel) were immunoprecipitated from lysates of the same transduced 
cells and then electrophoresed and probed with specific antibodies, 
as indicated. C) Human influenza hemagglutinin (HA)–tagged SH3∆ or 
SH3WD40∆ mutants were transfected into 293T cells with or without a 
Jak2 vector, immunoprecipitated with antibodies to either HA or Jak2, 
electrophoresed, and probed using Jak2 or Ahi-1 antibodies (left panel). 
The right panel shows that these two mutants were coexpressed with 
BCR-ABL, immunoprecipitated with an anti-HA antibody, and probed 
with a c-ABL antibody. A schematic of the functional domains of full-
length Ahi-1 and its SH3∆ and SH3WD40∆ mutants is below the right 
panel. IP = immunoprecipitation; WB = Western blotting.
Vol. 105, Issue 6  |  March 20, 2013410 Articles | JNCI
Figure 2. Effect of imatinib (IM) on induction of apoptosis and inhibition 
of colony formation in BCR-ABL–transduced cells coexpressing Abelson 
helper integration site 1 (Ahi-1) mutants and combined treatment with IM 
and a Janus kinase 2 (JAK2) inhibitor on inhibition of growth of AHI-1 
–overexpressing and IM-resistant cells. A) BCR-ABL–transduced cells 
coexpressing full-length Ahi-1 and its mutants were cultured with IM, 
and the treated cells were stained with Annexin V/7-aminoactinomysin 
(7-AAD) to detect apoptotic cells after 24 or 48 hours. Representative flu-
orescence-activated cell sorting plots showing detection of Annexin V/7-
AAD+ cells 24 hours after IM treatment are included. B) Transduced cells 
(200 cells/group) were pretreated with IM for 24 hours and then plated 
in colony-forming cell assays. Colony numbers produced in semisolid 
media were counted and expressed as a percentage of counts obtained 
from control cells without any drug added. C–E) Control K562 cells, AHI-
1–transduced SH4-bulk K562 cells (with suppressed AHI-1 expression), 
lenti-AHI-1 K652 cells (overexpressing AHI-1) and IM-resistant K562 cells 
were incubated with IM (C), or TG101209 (TG) alone (D), or both in combi-
nation (E), or with no drug for 48 hours and the percentage of viable cells 
was then measured. F) AHI-1 was immunoprecipitated from cell lysates 
of AHI-1–overexpressing K562 cells treated with IM and TG alone or in 
combination for 16 hours. The immunoprecipitates were then probed 
with an antityrosine phosphorylation antibody (4G10), a BCR-ABL anti-
body, a JAK2 antibody, and an AHI-1 antibody. Control cells  =  Hut78 
cells. Data are means, and error bars represent 95% confidence intervals 
from three independent experiments in triplicate. P values were calcu-
lated using a two-sided Student t test. WB = Western blotting.
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Viability of AHI-1–Overexpressing and IM-Resistant 
CML Cells Treated With IM and a JAK2 Inhibitor in 
Combination
We next asked whether targeting the AHI-1–BCR-ABL–JAK2 
interaction complex by combining IM treatment with exposure 
to a selective JAK2 inhibitor, TG (43), could enhance the final 
inhibitory effects achievable with either agent alone. Treatment 
of BCR-ABL+ K562 cells with graded doses of TG gave an IC50 
value for these cells of 0.5 µM (Supplementary Figure 2A, available 
online). Western blot analysis revealed that the levels of P-JAK2 
and P-STAT5 were greatly reduced in the presence of 5 µM after 
4 hours, whereas total JAK2 and STAT5 protein expression was 
still unaffected (Supplementary Figure  2B, available online). TG 
alone also inhibited the growth of primary CD34+ CML cells, with 
an IC50 value of 100 nM. Of note, CD34+ normal BM cells were 
less sensitive to TG, with an IC50 value of 250 nM (Supplementary 
Figure 2A, available online).
Interestingly, K562 cells engineered to stably overexpress AHI-1 
 (lenti-AHI-1) and IM-resistant K562 cells showed a reduced sen-
sitivity to both IM (at 5 µM) and TG (at 0.5 and 5 µM), as assessed 
by a cell viability assay (Figure 2, C and D), but the results were 
not statistically significant. In contrast, K562 cells engineered to 
stably suppress AHI-1 (SH4-bulk) showed a heightened sensitiv-
ity to IM at concentrations as low as 1 µM (percentage of viable 
cells in SH4 bulk cells vs control K562 cells: 13.8% vs 76.2%, dif-
ference = 62.4%, 95% CI = 30.7% to 60.2%, P < .001; 3.7% vs 
19% at 5 µM IM, difference = 15.3%, 95% CI = 0.4% to 30.2%, P 
.05). However, IM together with TG was more effective at killing 
AHI-1–overexpressing cells (IM vs IM + TG: 82% vs 31%, differ-
ence = 53.3%, 95% CI = 25.5% to 85.2%, P = .01; TG vs IM + TG: 
54% vs 31%, difference = 24%, 95% CI = 1.3% to 44.7%, P = .05) 
and IM-resistant K562 cells (IM vs IM + TG: 85% vs 22.3%, differ-
ence = 62.7%, 95% CI = 41.8% to 83.5%, P = .01; TG vs IM + TG: 
44.7% vs 22.3%, difference = 22.3%, 95% CI = 0.8% to 45.4%, 
P = .05) (Figure 2E). IM-resistant cells also expressed higher levels 
of AHI-1 protein than the parental K562 cells (Figure 3A). Both 
parental and AHI-1–suppressed cells showed a significant increase 
in sensitivity to combination treatment compared with TG alone 
(TG vs IM + TG: 24% vs 7.1%, difference = 17%, 95% CI = 9.5% 
to 25%, P  =  .01, and 22% vs 1.2%, difference  =  20.8%, 95% 
CI = 12.6 % to 29.1%, P = .01). Western blot experiments showed 
a biologically significant reduction in phosphorylation of CRKL, 
JAK2 and STAT5 in the AHI-1-overexpressing and IM-resistant 
K562 cells treated with IM plus TG, as compared to cells treated 
with IM or TG alone, while no change in phosphorylation of AKT 
and ERK was observed under the same conditions (Figure 3A). In 
addition, K562 cells and AHI-1–overexpressing cells treated either 
with TG alone or IM and TG together showed a marked reduction 
in AHI-1 and JAK2 protein expression. It was noticed that AHI-1 
protein expression was only slightly reduced by the combination 
treatment in IM-resistant K562 cells, possibly due to activation of 
BCR-ABL–independent pathways, including persistently activated 
Lyn kinase, Fyn/ERK, and c-CBL, as previously reported (44–47). 
Moreover, the combination treatment was also more effective at 
reducing phosphorylation and protein expression of BCR-ABL, 
JAK2, and AHI-1 in BV173 cells as compared with cells treated with 
IM or TG alone (Figure 3B, right panel). Coimmunoprecipitation 
experiments further confirmed a stable complex of AHI-1–BCR-
ABL–JAK2 in AHI-1–overexpressing K562 cells after immunopre-
cipitation with an anti-AHI-1 antibody (Figure 2F). Importantly, 
this protein interaction complex was markedly interrupted in the 
same cells treated with IM plus TG, as compared with cells treated 
with IM or TG alone. This resulted not only in a marked reduc-
tion in phosphorylation of BCR-ABL (Figure 2F, left panel), but 
also in reduction in protein expression of BCR-ABL, JAK2, and 
AHI-1 (Figure 2F, right panel). These results indicate that simulta-
neous treatment of BCR-ABL+ cells with IM and a JAK2 inhibitor 
destabilizes, and hence downregulates, the activity of the AHI-1–
BCR-ABL–JAK2 complex, leading to enhanced death of AHI-1–
overexpressing and IM-resistant BCR-ABL+ cells.
Effects of TG in Combination With TKIs on Very Primitive 
CML Patient Cell Survival
To determine whether the effects obtained using a combined BCR-
ABL–JAK2 targeting approach on cell lines would extend to pri-
mary CP CML cells, we isolated BCR-ABL+CD34+ cells from three 
patients’ samples obtained at diagnosis and then cultured these 
cells in liquid suspension with growth factors for 3 days in the pres-
ence of 5 µM IM, 5 µM NL, 150 nM DA, or 100 nM TG alone or in 
combination with TG. As expected, the percentages of viable cells 
present in cultures containing a single TKI or TG were lower than 
the values measured in the corresponding cultures to which no 
drug was added (TG, 38.1%, difference = 61.9%, 95% CI = 37.7% 
to 86.1%, P < .001; IM, 55%, difference = 48%, 95% CI = 23.8% to 
72.2%, P < .001; NL, 42.3%, difference = 57.7%, 95% CI = 33.5% to 
81.8%, P < .001: DA, 45.6%, difference = 54.4%, 95% CI = 30.2% 
to 78.6%, P < .001) (Figure 4A, left panel). However, the addition 
of TG to any TKI (regardless of the TKI type) resulted in a pro-
gressive reduction in the expansion of viable cells compared with 
TKI-only treated arms, with a clear dependence of the effect of 
the addition of TG over time (test for time–TG interaction, P < 
.001); the estimated relative reduction was 7% at 24 hours (95% 
CI = −12% to 22%), 13% at 48 hours (95% CI = −5% to 27%) 
and 49% at 72 hours (95% CI = 38% to 57%) (Figure 4A, right 
panel). No substantial toxic effects were observed in CD34+ cells 
from three normal individuals treated with TKI and TG alone or 
in combination during equivalent cultures (Figure 4A, lower pan-
els). Assessment of viability by Annexin V staining provided a more 
sensitive measure of the induction of apoptosis, with statistically 
significant differences apparent when comparing TG plus a TKI 
in combination with each single agent TKI treatment (IM vs IM + 
TG: 15.2% vs 40.5%, difference = 25.3%, 95% CI = 10% to 40.7%, 
P < .001; NL vs NL + TG: 19.5% vs 44.1%, difference = 24.65%, 
95% CI = 9.3 % to 40%, P < .001; DA vs DA + TG: 17.2% vs 
51.6%, difference = 34.3%, 95% CI = 19% to 49.6%, P < .001) 
(Figure 4B, left panel). These effects were not observed in CD34+ 
normal BM cells with the same treatments, including the combi-
nation treatments (Figure 4B, right panel). We also analyzed the 
CD34+CD38+ and CD34+CD38-/low subsets present in these 3-day 
cultures. Single agent treatments caused a reduction in the num-
ber of more-mature CD34+38+ progenitor cells, but more-primi-
tive 34+38low cells (a population with higher short-term expansion 
potential) and 34+38− cells (a stem cell–enriched population) were 
less sensitive to these agents alone (twofold and threefold fewer 
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Figure 3. Inhibition of phosphorylation of BCR-ABL, CRK-like (CRKL), 
Janus kinase 2 (JAK2), and signal transducer and activator of tran-
scription 5 (STAT5) in transduced K562 cells in response to combined 
treatment with TG101209 (TG) and imatinib (IM). A) K562 cells, Abelson 
helper integration site 1 (AHI-1)–overexpressing K562 cells, and 
IM-resistant K562 cells (IMR) were cultured with or without IM, TG, or a 
combination of IM and TG for 16 hours. Western blot analysis detected 
phosphorylation and protein expression of various proteins using the 
specific antibodies indicated. B) BV173 cells were treated with IM, TG, 
or IM plus TG for 16 hours. Cell lysates were immuno-probed with the 
specific antibodies indicated. GAPDH or actin was utilized as a loading 
control.
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cells in cultures with TKIs or TG, respectively, as compared with 
untreated controls after 3 days in culture). This is consistent with 
our previous observations that more-primitive CML cells were less 
sensitive to TKI treatment than their more-mature cells (33,48). 
However, combination treatment with TKI and TG reduced the 
numbers of the 34+38low cells compared with either of the single 
agents alone and, more strikingly, caused an absolute reduction in 
the number of 34+38− cells (>10-fold reduction) (Figure 5A). These 
Figure 4. Effects of TG101209 (TG) in combination with tyrosine kinase 
inhibitors (TKIs) on the viability and induction of apoptosis in primary 
CD34+ chronic myeloid leukemia (CML) cells. A) CD34+ CML cells (n = 3, 
upper left panel) and CD34+ normal bone marrow (BM) cells (n=3, 
lower left panel) were analyzed after 72 hours of drug exposure (solid 
bars  =  no added drug; checkered bars  =  drug added). Viable cell fre-
quencies were assessed by counting trypan dye–excluding cells. These 
were then expressed as a percentage of the frequency of viable cells 
in parallel cultures to which no drug was added (left panel) or used to 
calculate the total content of viable cells in the culture (right panel). B) 
Percentage of total apoptotic cells after 72 hours of drug treatment of 
CD34+ CML cells (n  =  3) and normal BM cells (n  =  3) determined by 
Annexin V/7-aminoactinomysin (7-AAD) staining. P values were calcu-
lated using one-way analysis of variance with correction for multiple 
group comparison for individual treatment arms (B). Data are means, 
and error bars represent 95% confidence intervals of triplicate measure-
ments. NL = nilotinib; DA = dasatinib.
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results suggest that combining TKI with TG has a more potent 
effect on the most primitive stem cell compartment.
Next we asked whether the combination of TG plus a TKI 
could also target primary CML CFCs. We first incubated CD34+ 
CML cells with TKIs alone, or with TG plus a TKI, for 3 or 6 days. 
An aliquot was then plated in growth factor–supplemented methyl-
cellulose medium to determine the number of CFCs present. After 
a 3-day exposure, a 37% relative reduction of the CFC recovered 
Figure 5. Effects of TG101209 (TG) in combination with tyrosine kinase 
inhibitors (TKIs) on multiple subsets of CD34+  chronic myeloid leuke-
mia (CML) cells. A) CD34+ CML cells (n = 3) were cultured for 72 hours 
in the presence of imatinib (IM), nilotinib (NL), dasatinib (DA), or TG 
alone or a combination of TKI with TG, and the phenotypes of cells pre-
sent within the viable (AnnexinV-/7-aminoactinomysin [7-AAD-]) gate 
were then determined by fluorescence-activated cell sorting based on 
their expression of CD34 and CD38. The total number of viable cells 
within each subpopulation was then calculated based on viable cell 
counts at 72 hours and compared with the starting number of cells 
within each subpopulation (baseline), represented by the red line. 
B–C) CD34+ CML cells (n = 2) (B) from newly diagnosed chronic-phase 
patients and CD34+ normal bone marrow (n  =  3) (C) were plated in 
standard colony-forming cell (CFC) assays after 3 (left) or 6 (right) days 
of prior incubation in suspension cultures with 5 µM IM, 150 nM DA, 
5 µM NL, or 100 nM TG alone or in combination. Colonies produced in 
the CFC assays were counted after 12 to 14 days of further incubation, 
and the numbers obtained are expressed as a percentage of values 
obtained in control assays without drug added. Data are means, and 
error bars represent 95% confidence intervals of triplicate measure-
ments. P values were calculated using methods appropriate to fitting 
linear mixed models.
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with TKI alone was recorded when TG was added to TKI (95% 
CI= −24% to 68%, P = .18). However, after a 6-day exposure, this 
increased to 86% (95% CI = 72% to 93%, P < .001), with a clear 
dependence of the effect of the addition of TG over time (test for 
time–TG interaction, P = .003) (Figure 5B). A toxic effect on CFC 
output of CD34+ normal BM cells was noted when adding TG to 
TKI. The magnitude of this effect was similar to that seen on CML 
CD34+ cells after 3 days, but importantly was not enhanced over 
time, with no further reduction in the number of colonies observed 
in the combination arm after 6 days of culture (44% relative reduc-
tion (95% CI = 29% to 56%, P < .001; test for time–TG interac-
tion, P  =  .19) (Figure  5C). These results indicate that TKI plus 
TG is more effective at eliminating primary CML stem/progenitor 
cells than single TKIs, including cells that generate CML CFCs in 
short-term cultures; this effect is enhanced over time. Moreover, 
using a carefully selected concentration of TG, only a moderate 
toxic effect on normal BM was observed, which did not increase 
over time, thus providing a therapeutic window for the combina-
tion arm.
Elimination of Treatment-Naive CML Stem/Progenitor 
Cells From Clinically Defined IM Nonresponder Patients 
Using TG in Combination With a TKI
To determine whether simultaneously targeting both BCR-ABL 
and JAK2 activities could be therapeutically effective for CP 
patients who do not respond adequately to treatment with a single 
TKI, we investigated CML cells obtained at diagnosis from four 
CP patients who were classified retrospectively, after initiation of 
IM therapy, as clinical nonresponders (Supplementary Table  2, 
available online). The number of CFC colonies obtained in cultures 
containing TG or TKIs alone was reduced from the control value 
by less than 50% (Figure 6A), as expected (49). However, when TG 
plus a TKI was present, a statistically significant greater reduction 
in colony formation was seen (mean CFC yields of IM vs IM + TG: 
54% vs 16%, difference = 39%, 95% CI = 35% to 68%, P < .001; 
DA vs DA + TG: 44% vs 11%, difference = 33%, 95% CI = 33% 
to 64%, P < .001; NL vs NL + TG: 59% vs 17%, difference = 43%, 
95% CI = 30% to 65%, P < .001) (Figure 6A, left panel). It was 
interesting to note that treatment with a combination of TKIs, IM 
plus DA or IM with NL, was not effective at reducing CFC num-
bers from IM nonresponders. To assess effects on more primitive 
LTC-ICs, we incubated the initially isolated CD34+ cells for 3 days 
in suspension culture, with growth factors and TG or TKIs alone 
or in combination, and then harvested the cells and plated equal ali-
quots in LTC-IC assays. The CFC outputs obtained 5 weeks later 
showed even less evidence of an effect of single-agent treatment 
on the LTC-IC numbers present in the 3-day cultures (Figure 6B). 
However, a statistically significant reduction in LTC-IC–derived 
colony yields was obtained with any of the combination treatments 
(mean LTC-IC–derived CFCs of IM vs IM + TG: 72% vs 26%, 
difference = 46%, 95% CI = 32% to 65%, P < .001; DA vs DA 
+ TG: 59% vs 18%, difference = 40%, 95% CI = 30% to 69%, 
P < .001; NL vs NL + TG: 62% vs 22%, difference = 41%, 95% 
CI = 35% to 68%, P < .001). Importantly, toxic effects were not 
observed in experiments initiated with CD34+ cells from normal 
individuals (Supplementary Figure  3A, available online). These 
results indicate that combination treatment with TKI and TG is 
effective at targeting very primitive CML stem/progenitor cells 
from IM nonresponders before they display evidence of resistance.
Effects of Combined Exposure of CD34+ CML Cells to TG 
and a TKI on Suppression of BCR-ABL and JAK2/STAT5 
Activities
We then examined changes in the phosphorylation of CRKL and 
STAT5, as indicators of BCR-ABL kinase activity. P-STAT5 is also 
activated by JAK2 kinase and can therefore be used as a measure 
of JAK2 kinase activity. The levels of phosphorylation of P-CRKL 
and P-STAT5 were analyzed in CD34+ cells isolated from three 
CML samples after 24 hours incubation with no drug, or TG or 
one of the three TKIs alone, or in combination. We found that 
the levels of P-STAT5 were statistically significantly reduced 
upon addition of TG to TKI when compared with TKI treatment 
alone (35% relative reduction, 95% CI = 12% to 53%, P < .001), 
whereas the reduction in P-CRKL levels was marginally non-sta-
tistically significant (20% absolute reduction in phosphorylation 
rates [expressed as a percentage of baseline], 95% CI  =  −4% to 
45%, P = .11). These combination effects were enhanced following 
another 48 hours of drug exposure, demonstrating the dependence 
of the effect of the addition of TG on time (P-CRKL: 60% abso-
lute reduction in phosphorylation rates [expressed as a percentage 
of baseline], 95% CI = 35% to 84%, P < .001; and P-STAT5: 55%, 
95% CI  =  39% to 67%, P < .001). The respective tests for TG 
dependence on time are statistically significant for both P-CRKL 
(P = .03) and P-STAT5 (P = .03) (Figure 6C). Addition of TG to 
TKI treatment also caused a reduction in P-STAT5 levels after 24 
hours in normal CD34+ cells, which express relatively low levels of 
P-STAT5. However this reduction was not as great as that observed 
in CML CD34+ cells in equivalent cultures (21% relative reduction 
compared with TKI, CI = 9% to 31%, P = .004) (Supplementary 
Figure 3B, available online). These results indicate that combined 
TG and TKI treatment markedly and durably inhibits the activity 
of BCR-ABL and JAK2 in CML stem/progenitor cells and to a 
higher degree than in normal cells.
Survival of Leukemic Mice Treated With TG and IM
To more definitively test the ability of TG in combination with a 
TKI (IM) to eliminate CML cells with in vivo leukemia propagat-
ing activity, we first undertook an experiment in which BV173 cells 
were exposed to these drugs for 3 days in vitro and then assayed 
posttreatment for their ability to produce leukemic progeny in 
NOD/SCID–interleukin 2 receptor γ–chain-deficient (NSG) 
mice. BV173 cells (derived from a BM sample of a CML blast crisis 
patient), but not K562 cells, have been shown to generate a lethal 
leukemia in NOD/SCID mice (50), and NSG mice are even more 
permissive to repopulation by leukemic cells, compared with nor-
mal human hematopoietic cells (51). Accordingly, 2.5 × 106 BV173 
cells were cultured with or without 1 µM IM alone, 0.5 µM TG 
alone, or IM plus TG at the same concentrations for 3 days, fol-
lowed by injection of all of the cells present at that time (ie, all of 
the progeny derived from the 2.5 × 106 input cells) into sublethally 
irradiated NSG mice (n = 6 mice per condition). Three weeks later, 
there were no statistically significant differences in the frequency of 
human BCR-ABL+CD19/CD20+ (BV173) cells in the BM of mice 
transplanted with IM- or TG-pretreated cells, as compared with 
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recipients of control cells (incubated for 3 days without any drug) 
(Figure  7A). However, by comparison, the BM of mice injected 
with cells that had been exposed to IM and TG in combination 
contained fewer human CD19/CD20+ cells (0.04% compared with 
18% from untreated control cells, 6.2% for IM alone, and 15% for 
TG alone). We observed that mice injected with untreated cells died 
within 53  days, demonstrating the relatively aggressive nature of 
this CML model. A trend toward prolonged survival was observed 
in mice injected with the TG- plus IM-treated cells, but this differ-
ential effect did not achieve statistical significance (data not shown).
Figure  6. Proliferation of primitive chronic myeloid leukemia (CML) 
cells from clinically tyrosine kinase inhibitors (TKI)–resistant patients 
and CRK-like (CRKL) and signal transducer and activator of transcrip-
tion 5 (STAT5) phosphorylation in these cells in response to combina-
tion treatment with TG101209 (TG) and TKI. A) CD34+ CML cells from 
four newly diagnosed chronic-phase patients, subsequently classified 
clinically as imatinib (IM) nonresponders, were plated in standard 
colony-forming cell (CFC) assays plus 5 µM IM, 150 nM dasatinib (DA), 
5 µM nilotinib (NL), or 100 nM TG alone or in combination. Colonies pro-
duced were counted after 12 to 14 days of incubation, and the numbers 
obtained were expressed as a percentage of values obtained in control 
assays to which no drugs were added. B) CD34+ CML cells from three 
patients studied in (A) were incubated for 3 days in suspension cultures 
with 5 µM IM, 150 nM DA, 5 µM NL, or 100 nM TG alone or in combi-
nation and then assayed for long term culture-initiating cells (LTC-ICs). 
LTC-IC–derived CFC values were derived from the LTCs harvested 5 
weeks later and then expressed as a percentage of the LTC-IC CFC num-
bers obtained for cells initially incubated for 3 days in the absence of 
any added drug. C) Phosphorylation of CRKL (upper panels) and STAT5 
(lower panels) in CD34+ CML cells (n  =  3) was measured by fluores-
cence-activated cell sorting after 24 and 72 hours of drug exposure and 
expressed as a percentage of cells incubated for the same time in the 
absence of any drug. Data are means, and error bars represent 95% 
confidence intervals from three independent experiments in triplicate. 
P values were calculated using a two-sided Student t test (A and B) or 
methods appropriate to fitting linear mixed models (C).
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Figure 7. Effects of oral administration of TG101209 (TG) and imatinib 
(IM) on elimination of chronic myeloid leukemia (CML) BV173 cells and 
survival of leukemic mice in immunodeficient mice. A) BV173 cells were 
cultured with 1.0 µM IM, 0.5 µM TG, IM plus TG, or no drug for 3 days, 
and the progeny recovered from 2.5 × 106 initial cells were then injected 
intravenously into NOD/SCID–interleukin 2 receptor γ–chain-deficient 
(NSG) mice (n  =  6 mice per condition). The left panel shows fluores-
cence-activated cell sorting profiles of engrafted human CD19/20+ cells 
detected in bone marrow aspirates of representative mice obtained 3 
weeks posttransplant. The percentage of human CD19/20+ BV173 cells 
detected in the bone marrow of mice examined 3 weeks after injection 
is shown in the right panel. Data are means, and error bars represent 
95% confidence intervals of six measurements per condition. B) Survival 
curve for recipients of BV173 cells (2.5 × 106 per mouse; n = 6 mice per 
group) treated by oral gavage beginning at 2 weeks posttransplant with 
vehicle, IM (50mg/kg), TG (60mg/kg), and IM (50mg/kg) plus TG (60mg/
kg) twice a day for 2 weeks. Statistically significantly prolonged survival 
was observed in mice receiving the combination treatment (left panel). 
Body weights of mice in each treated group were measured, as indi-
cated in the right panel. Log-rank tests were used to compare median 
survival of different groups (n = 6 mice per group), and P values were 
calculated using a two-sided Student t test. C) Model of the mechanism 
by which Abelson helper integration site 1 (AHI-1)–BCR-ABL and AHI-1–
Janus kinase 2 (JAK2) interactions regulate constitutive activation of 
BCR-ABL and JAK2/ signal transducer and activator of transcription 5 
(STAT5), resulting in increased leukemic stem cell proliferation, survival 
and maintenance and reduced tyrosine kinase inhibitor (TKI) response 
of these cells. Targeting both BCR-ABL and JAK2 activities to destabilize 
this complex perturbs these biological properties. IL-3  =  interleukin 3; 
IL-3R = interleukin 3 receptor.
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To improve the in vivo treatment effect in this aggressive CML 
model system, we assessed an oral treatment approach. The same 
numbers of BV173 cells (2.5 × 106) were injected into NSG mice. 
After about 2 weeks, mice were given oral gavage treatment with 
IM monotherapy (50 mg/kg), TG monotherapy (60 mg/kg), or 
IM plus TG combination therapy twice a day for 2 weeks (n = 6 
mice per condition, including vehicle control). Interestingly, we 
observed statistically significantly prolonged survival in mice 
treated with the combination as compared with mice treated 
with TG or IM alone (median survival of IM + TG vs untreated: 
63 days vs 53 days, ratio = 0.84, 95% CI = 0.56 to 1.1, P = .002; TG: 
53 days, ratio = 0.84, 95% CI = 0.6 to 1.1, P = .004; IM: 57 days, 
ratio = 0.9, 95% CI = 0.61 to 1.2, P =.003) (Figure 7B, left panel). 
In addition, mice treated with the combination showed a reduc-
tion in weight loss compared with mice treated with single agents 
(Figure 7B, right panel). These results indicate that the oral com-
bination treatment is more effective than either alone in eliminat-
ing human CML cells that are capable of generating an aggressive 
leukemia in mice, with statistically significant enhanced survival of 
leukemic mice.
Effects of the Combination of TG Plus IM on CML LSCs 
With In Vivo Leukemia-Initiating Activity
We then undertook additional experiments to determine the effect 
of combined TG plus IM treatment on the subsequent in vivo leuke-
mogenic activity of primary CP CML cells transplanted into NSG 
mice. CD34+ CML cells (6 × 106 per treatment condition) from three 
CML patients who were subsequently classified as nonresponders 
after IM therapy were exposed to 1.0 µM IM, 100 nM TG, or both 
together for 3 days. The cells recovered from the 3-day drug expo-
sure cultures were then injected into sublethally irradiated NSG 
mice (n = 3 mice per group for each patient sample). IM plus TG 
treatment of primary CD34+ CML cells in vitro greatly reduced 
the levels of human CD45+ and CD34+ leukemic cells regenerated 
in the BM of transplanted NSG mice, as measured for 16 weeks, 
compared with cells pretreated with IM or TG alone (Figure 8A). 
Engrafted myeloid cells (CD14+CD15+CD33+CD66b+) appeared 
to be reduced to a greater extent in the BM of mice treated with the 
drug combination, as compared with single-agent treatments (0.7% 
vs 2.2 to 3.6%) (Figure 8, B and C), and CD34+ cells, in particular, 
were almost undetectable in the BM of mice injected with cells that 
had been pretreated with the TG plus IM combination at 16 weeks 
(Figure 8A, lower panel). Quantitative reverse-transcription PCR 
analysis further demonstrated statistically significant reductions in 
BCR-ABL transcript levels in FACS-purified CD45+ BM cells of 
mice injected with CML cells treated with the combination of TG 
plus IM, as compared with mice injected with the same patients’ 
cells pretreated with IM or TG alone or maintained in a medium 
without either agent (BCR-ABL transcript levels measured at 4 
weeks, IM vs IM + TG (undetectable): 0.76 vs 0, difference = 0.76, 
95% CI = 0.64 to 0.84, P < .001; TG, 0.53, difference = 0.53, 95% 
CI = 0.34 to 0.7, P < .001; at 12 weeks, IM vs IM + TG = 7.8 vs 
0.3, difference= 7.5, 95% CI = 5.9 to 9.1, P < .001) (Figure 8D). 
Notably, BCR-ABL transcripts were increased in mice treated with 
IM at 12 weeks, indicating a lack of a biologically significant effect 
on the LSCs. Fluorescence in situ hybridization analysis con-
firmed that more than 90% of the human cells obtained from mice 
transplanted with CML cells not exposed to drug were BCR-ABL+. 
These results show that the combined treatment with IM plus TG 
more effectively eliminates CML LSCs than IM or TG alone.
Discussion
In this study, we provide new evidence for AHI-1’s role in medi-
ating TKI response of CML cells by identifying independent 
AHI-1–JAK2 and AHI-1–BCR-ABL interactions that directly link 
these two kinases and AHI-1 in CML cells. Specifically, we show 
that loss of the ability of AHI-1 to interact with BCR-ABL, via its 
WD40-repeat and SH3 domains, substantailly enhances the apop-
totic response and inhibits proliferation of BCR-ABL+ cells exposed 
to TKIs (Figure 2). These findings provide a molecular mechanism 
to explain our previous observation that full-length Ahi-1/AHI-1 
mediates both the transforming activity of BCR-ABL in primitive 
hematopoietic cells and the IM resistance characteristics of CML 
stem/progenitor cells through activation of the BCR-ABL and 
JAK2/STAT5 pathway (39). A number of recent studies of other 
WD40-repeat–containing scaffold proteins (52,53) reinforce the 
concept that AHI-1 serves as a regulator of the TK activity of both 
BCR-ABL and JAK2. For example, MORG1, a binding partner 
of the ERK pathway scaffold protein MP1, interacts with multi-
ple components of the ERK cascade (MP1, Raf-1, MEK1, MEK2, 
ERK1, and ERK2) to stabilize their assembly into an oligomeric 
complex that regulates numerous cellular functions in normal and 
cancerous cells (52). RACK1, another WD40-containing protein, 
interacts with ABL only in transformed cells, and the introduction 
of RAS enhances this association of RACK1 with ABL, mediating 
altered signaling activities (54). In addition, truncating mutations 
that delete the WD40-repeat and SH3 domains of AHI-1 underlie 
Joubert syndrome (55,56), a disease that may be mediated by an 
AHI-1 and HAP1 molecular complex (57). In this study, we have 
shown that disrupting the interaction between AHI-1 and BCR-
ABL statistically significantly increased IM-induced apoptosis and 
reduced proliferation in BCR-ABL–transduced cells, indicating a 
positive regulatory role for the WD40 repeats in modulating IM 
response in CML. Of particular note is our previous observation 
that the highest levels and activity of endogenous BCR-ABL and 
AHI-1 occur in CML LSCs, with progressive downregulation 
as the cells differentiate (22,34,36). This finding suggests that it 
is crucial to the AHI-1–BCR-ABL cooperative activities in CML 
LSCs to generate a rapidly expanding clone of deregulated LSCs 
that are intrinsically more resistant to TKI treatment than their 
more-mature cells, potentially contributing to disease progression 
and drug resistance (Figure 7C).
Our finding that deletion of the N-terminus of AHI-1 prevents 
it from interacting with JAK2 in BCR-ABL+ cells and sensitizes 
the cells to the apoptosis-inducing activity of IM implicates the 
AHI-1–JAK2 interaction in the innate IM-resistant phenotype of 
primitive human CML cells. However, we also showed that dis-
ruption of the ability of AHI-1 to interact with BCR-ABL has an 
even more pronounced effect on IM sensitivity than disruption of 
AHI-1’s ability to interact with JAK2. This may be because of the 
reported ability of JAK2 to interact directly with BCR-ABL via its 
C-terminus in certain cell lines and thereby independently promote 
the transforming activity of BCR-ABL (7). The BCR-ABL–JAK2 
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Figure  8. Elimination of chronic myeloid leukemia (CML) leuke-
mic stem cells capable of long-term production of BCR-ABL+ cells in 
immunodeficient mice using combined exposure to TG101209 (TG) 
and imatinib (IM). A) CD34+ cells from three CML patients were cul-
tured with 1.0 µM IM, 0.1 µM TG, IM plus TG, or without treatment for 
3 days. Cells recovered were injected intravenously into NOD/SCID–
interleukin 2 receptor γ–chain-deficient (NSG) mice (n  =  3 mice per 
condition per patient sample). After 4, 8, 12, and 16 weeks, bone mar-
row (BM) aspirates were obtained, and the presence of human CD45+ 
and CD34+ cells was measured. B) Fluorescence-activated cell sorting 
profiles of regenerated human myeloid cells (CD45/CD14/15/33/66b+) 
in the BM of representative mice analyzed 12 weeks posttransplant. C) 
The percentage of human myeloid (CD45/CD14/15/33/66b+) and lym-
phoid cells (CD45/CD19/20+) in the BM of representative mice analyzed 
4 weeks posttransplant. D) BCR-ABL transcript levels measured by 
quantitative reverse transcription polymerase chain reaction in fluo-
rescence-activated cell sorting–purified human CD45+ cells obtained 
at 4 and 12 weeks posttransplant from the BM of mice injected with 
cells treated with inhibitors and those without. Data are means, and 
error bars represent 95% confidence intervals of six to nine meas-
urements per condition. P values were calculated using a two-sided 
Student t test.
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complex may thus be able to compensate, to some extent, for the 
sensitizing effect that disrupting the AHI-1–JAK2 interaction has 
on IM-induced apoptosis of BCR-ABL+ cells. Interestingly, a recent 
study suggests that the BCR-ABL–mediated signaling pathways in 
CML cells are controlled by JAK2 through direct phosphorylation 
of tyrosine 177 of the BCR-ABL oncoprotein (9). It is unlikely 
that AHI-1 directly interacts with tyrosine 177 of BCR-ABL to 
mediate drug response of CML cells because AHI-1 doesn’t con-
tain a SH2 domain, which is required for interaction with tyrosine 
177 of BCR-ABL, but rather interacts with BCR-ABL through the 
WD40 domain of AHI-1, as demonstrated in this study. However, 
it still remains to be determined if AHI-1 may regulate BCR-ABL 
activity through Y177 indirectly or through JAK2. Nevertheless, 
the observation of markedly increased apoptosis and reduced 
proliferation of BCR-ABL+ cells exposed to TKIs by interrupting 
both AHI-1–JAK2 and AHI-1–BCR-ABL interactions indicates 
that AHI-1–mediated protein–protein interactions are required to 
mediate response/resistance of CML cells to TKIs (Figure 7C).
Thus, targeting JAK2 activity could be an ideal strategy to com-
plement the inhibition of TK activity of BCR-ABL in primary 
CML stem and progenitor cells because the insensitivity of these 
cells to single TKI treatment is a potential source of disease per-
sistence and relapse (Figure 7C) (8,14,15,26,27,58). Interestingly, 
BCR-ABL has been found to interact with the IL-3/GM-CSF 
receptor, which then contributes to the downstream activation of 
JAK2 (59). In addition, in primitive CML cells, BCR-ABL expres-
sion stimulates the production of IL-3, G-CSF, and GM-CSF, 
which, following binding to their cognate receptors, further con-
tribute to CML progenitor cell resistance to TKIs by activation 
of the JAK2/STAT5 pathway (60,61). Recently, high STAT5 levels 
were also found to mediate acquired IM resistance in CML cells, 
and the STAT5 inhibitor, pimozide, was shown to reduce their sur-
vival (62,63).
Consistent with this prediction, we found that treatment of 
AHI-1–overexpressing K562 cells and IM-resistant K562 cells (no 
detectable BCR-ABL–TK mutations, but with increased expres-
sion of BCR-ABL and AHI-1) with IM in combination with a JAK2 
inhibitor (TG) was more effective at inhibiting the growth of these 
cells than the same dose of either drug on its own. This enhanced 
inhibition of growth was mirrored by a correspondingly enhanced 
reduction in BCR-ABL, CRKL, JAK2, and STAT5 phosphoryla-
tion in the same cells treated with IM plus TG, as compared with 
those treated with IM or TG alone (Figure 2 and 3). Reduced pro-
tein expression of AHI-1 and JAK2 was also observed as a result 
of treatment with TG alone or the combination. Importantly, the 
AHI-1–BCR-ABL–JAK2 protein interaction complex was mark-
edly interrupted in CML cells with IM plus TG, as compared with 
cells treated with IM or TG alone (Figure  2F). Together, these 
results indicate that dissociation of BCR-ABL and JAK2 kinases 
from AHI-1 can sensitize BCR-ABL+ cells to IM. Additional experi-
ments, using primary CML cells and both short- and long-term 
readouts in vitro and in vivo, confirmed that, in every case, the same 
drugs together were more effective in targeting early CML stem/
progenitor cells than a TKI or JAK2 inhibitor alone. Combination 
treatment with TKIs to target BCR-ABL TK activity alone (IM 
plus DA or NL) was not able to achieve the statistically significant 
effects seen in CML stem/progenitor cells in response to targeting 
both BCR-ABL and JAK2 (Figure 6A). In particular, the TKI and 
TG combination resulted in statistically significant depletion of 
P-CRKL and P-STAT5 activity in CML stem/progenitor cells, as 
compared with TKIs alone (Figure 6C), providing further molecu-
lar evidence that suppressing both BCR-ABL and JAK2 activities in 
CML stem/progenitor cells is critical for eradication of these cells.
We also asked whether the combination of TG plus TKI treat-
ment might be a better treatment strategy for CP patients who may 
be unlikely to respond to single TKIs because TKIs would fail to 
significantly reduce the LSC population. Such patients might thus 
benefit from a treatment that could effectively reduce the CML 
LSC burden, thereby escaping the development of TKI-resistant 
CML LSC. Our analysis of treatment-naive CD34+ cells isolated 
from CML samples obtained at diagnosis from patients who sub-
sequently proved to be clinically unresponsive to IM therapy pro-
vides direct support for this hypothesis. Even in cells from such 
patients, we found that TKI and TG in combination were capa-
ble of markedly reducing the numbers of TKI-resistant colonies 
in vitro and depleting their more-primitive precursors, including 
LTC-ICs and CML LSCs, capable of regenerating sustained pop-
ulations of BCR-ABL+ cells in NSG mice. Our study thus suggests 
an attractive strategy of TKI and TG in combination for treat-
ing CP CML patients who may develop IM resistance later. On 
the other hand, this combination may be less suitable for treating 
certain types of TKI-resistant patients whose resistance is due to 
the presence of a mutant kinase that is not responsive to known 
TKIs; in this case, a strategy that successfully targeted JAK2 may 
not be sufficient to be therapeutically effective. However, it has 
recently been reported that ponatinib, a third-generation of TKI, 
and DCC-2036, a “switch-control” inhibitor that potently inhib-
its both unphosphorylated and phosphorylated ABL by inducing a 
type 2 inactive conformation, retain efficacy against the majority of 
clinically relevant TKI-resistant mutants, including T315I (64,65). 
Their efficacy at targeting CML stem/progenitor cells remains to 
be determined. Because increased JAK2 activity and expression 
were observed in IM-resistant CML cells, a combination of DCC-
2036 (or ponatinib) and TG may thus be an ideal approach to elim-
inate these critical resistant stem/progenitor cells. Interestingly, in 
vivo administration of TG and IM by 2-week oral treatment was 
highly effective in eliminating BV173 CML cells that can generate 
an aggressive leukemia in mice. A statistically significant prolonged 
survival of treated mice was obtained by the combination, whereas 
IM or TG alone was ineffective at preventing disease development 
(Figure 7B). These results suggest that the combination treatment 
may be more effective at targeting more-aggressive leukemic cells 
present in late stages of CML because it has been challenging to 
treat these late-stage patients by IM monotherapy (8,14,15,66).
The JAK2 inhibitor (TG) was originally designed to target 
JAK2 mutations in myeloproliferative disorders and has been 
reported to be highly effective against the JAK2 V617F muta-
tion in polycythemia vera progenitors (67–69). In this study, we 
found that TG by itself had limited effects on inhibition of primary 
CD34+ CML cells when the concentration of TG was nontoxic 
to primitive normal BM cells. This difference could be due to the 
BCR-ABL–mediated activation of other pathways in primitive 
CML cells, potentially including downstream effects on STAT5 
in a JAK2 activation-independent manner (62,70). The additional 
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finding that AHI-1 strongly associates with JAK2 in the absence of 
BCR-ABL suggests that an AHI-1–JAK2 interaction may also play 
a role in regulating primitive normal hematopoietic cell signaling. 
This possibility is further reinforced by the finding that expres-
sion of AHI-1 is normally downregulated during the initial phase 
of hematopoietic cell differentiation (36).
Some potential limitations of this study should be considered. 
First, the in vitro and in vivo studies of CML stem/progenitor cell 
response to TKIs and a JAK2 inhibitor presented here were con-
fined to a relatively small number of CP CML patients’ samples. 
These data are not robust, and the results must therefore be inter-
preted with due caution. In addition, leukemic stem and progenitor 
cell numbers vary from patient to patient, and this may directly 
affect response/resistance of these cells to single and combination 
treatments. A second limitation of this study is that the therapeutic 
window for the JAK2 inhibitor TG102109 is relatively small and 
there is a need for the development of more selective and less toxic 
JAK2 inhibitors. Nevertheless, it is of considerable interest that the 
combined effect of TKI and TG on primitive CML stem/progeni-
tor cells is consistently superior (inhibitory) to their exposure to 
either agent alone. Taken together, the results strongly support 
a therapeutic role for TG plus a TKI, leading to more complete 
disease eradication for CML patients, particularly for those who 
are likely to develop TKI-resistant subclones if treated with a TKI 
alone.
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